Bromocriptine: low-dose therapy in Parkinson disease

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinson disease is a progressive neurodegenerative disorder.
• Current treatments like levodopa can have significant side effects.

Purpose of the Study:

• To evaluate the efficacy and safety of low-dose bromocriptine in idiopathic Parkinson disease.
• To compare bromocriptine's effects in levodopa-treated and de novo patients.

Main Methods:

• Double-blind, placebo-controlled trial.
• Involved 25 patients with idiopathic Parkinson disease.
• Assessed tremor, bradykinesia, and rigidity, with dose titration.

Main Results:

• Significant improvement in tremor and bradykinesia for all patients.
• Rigidity showed greatest improvement in levodopa-treated subjects.
• Adverse effects (30%) were mild and dose-dependent; slow titration improved tolerability.

Conclusions:

• Low-dose bromocriptine is an effective treatment for Parkinson disease.
• It offers an alternative to levodopa, without inducing significant dyskinesia or on-off phenomena.
• Slow dose escalation is recommended for optimal tolerability and efficacy.